Beating malaria

Scientist

Volumn 20, Issue 12, 2006, Pages 26-33

  Goozner, Merrill ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

EID: 33846082222     PISSN: 08903670     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (7)

1. See, for instance, R. McGready et al., "A randomized comparison of artesunate-atovaquone-proguanil versus quinine in treatment for uncomplicated falciparum malaria during pregnancy," J Infect Dis, 192:846-53, 2005.
2. For the earliest published result of a randomized clinical trial using artemisinin-based combination therapy, see F. Nosten et al., "Treatment of multidrug-resistant Plasmodium falciparum malaria with 3-day artesunate-mefloquine combination," J Infect Dis, 170:971-7, 1994.
3. A.V. Pandey et al., "Artemisinin, an endoperoxide antimalarial, disrupts the hemoglobin catabolism and heme detoxification systems in malarial parasite," J Biol Chem, 274:19383-8, 1999.
4. V.I. Carrara et al., "Deployment of early diagnosis and mefloquine-artesunate treatment of falciparum malaria in Thailand: the Tak malaria initiative," PLoS Med, 3:e183, June 6, 2006.
5. R. Hutagalung et al., "A randomized trial of artemether-lumefantrine versus mefloquine-artesunate for the treatment of uncomplicated multi-drug resistant Plasmodium falciparum on the western border of Thailand," Malaria J, Sept. 22, 2005 (www.malariajournal.com/content/4/1/46, accessed Nov. 4, 2006).
6. H. Noedl, "Artemisinin resistance: how can we find it?" Trends Parasitol, 21:404, 2005.
7. N.J. White, "Assessment of the pharmacodynamic properties of antimalarial drugs in vivo," Antimicrob Agent Chemother, 41:1413-22, 1997.